drugset / Trial / NCT07325591

Efficacy and Safety of Tazbentetol in ALS Participants

NCT07325591 ↗

Phase 2/3 Not yet recruiting 430 enrolled Spinogenix
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objectives of this study are to examine the effects of tazbentetol on clinical measures of ALS, patient reported outcomes (PROs), long-term safety and tolerability.

Timeline

Start
2026-03-01
Primary completion
2027-12-31
Completion
2028-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tazbentetol Unknown — Oral